James Hays, MD
Cardiovascular Disease · Jackson, MSNPI 1912943945
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (49.4%), consulting fees and speaking fees — rather than concentrated in one kind of arrangement. 35 manufacturers reported payments, led by Edwards Lifesciences at 44.1% of the total. Reporting peaked in 2019 at $6,232 and has fallen 51.4% since, to $3,030 in 2025.
Across 311 payments — averaging $52.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Edwards Lifesciences$7K
- Amgen$2K
- Novartis$2K
- Medtronic$1K
- Abiomed$983
- Boston Scientific$741
- plus $3K from 29 others
Across 72 payments — averaging $677.20 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boehringer Ingelheim International GmbH$18K
- Novartis$18K
- Amgen$9K
- Boehringer Ingelheim Pharma GmbH & Co.kg$4K
What the payments were for
- Consulting fees$4,57528%
- Speaking & faculty fees$2,50015%
- Travel & lodging$1,1627%
- Food & beverage$8,05649%
- Education$100%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Edwards Lifesciences | 7 | $7,193 |
| Amgen | 23 | $1,685 |
| Novartis | 97 | $1,583 |
| Medtronic | 59 | $1,392 |
| Abiomed | 22 | $983 |
| Boston Scientific | 9 | $741 |
| Merck | 18 | $415 |
| AstraZeneca | 8 | $255 |
| Glaukos Corporation | 1 | $187 |
| Novo Nordisk | 4 | $186 |
| Pfizer | 11 | $180 |
| Johnson & Johnson | 12 | $164 |
| Abbott | 7 | $154 |
| Inspire Medical Systems, Inc. | 1 | $132 |
| Shockwave Medical, Inc | 1 | $132 |
| Boehringer Ingelheim | 2 | $113 |
| Atricure, Inc. | 1 | $111 |
| Bayer | 2 | $110 |
| Philips North America LLC | 6 | $99 |
| Irhythm Technologies, Inc. | 1 | $86 |
| Akcea Therapeutics, Inc. | 1 | $71 |
| E.r. Squibb & Sons, L.L.C. | 4 | $62 |
| Heartflow, Inc. | 1 | $52 |
| Actelion Pharmaceuticals US, Inc. | 1 | $29 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $26 |
| Cvrx, Inc. | 1 | $22 |
| Lexicon Pharmaceuticals, Inc. | 1 | $19 |
| Impulse Dynamics (USA) Inc. | 1 | $18 |
| GSK | 1 | $17 |
| Chiesi USA, Inc. | 1 | $16 |
| Sanofi-aventis U.S. LLC | 1 | $15 |
| Regeneron Healthcare Solutions, Inc. | 1 | $15 |
| Kowa Pharmaceuticals America, Inc. | 1 | $14 |
| Daiichi Sankyo Inc. | 1 | $13 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$16,303 in reported general payments places this provider in the 80th percentile of 144 cardiovascular disease providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 832 | $611,866 |
| EntrestoSacubitril/Valsartan | 293 | $233,871 |
| XareltoRivaroxaban | 199 | $165,815 |
| JardianceEmpagliflozin | 192 | $130,672 |
| FarxigaDapagliflozin Propanediol | 134 | $89,865 |
| BrilintaTicagrelor | 46 | $25,119 |
| Repatha SureclickEvolocumab | 33 | $22,014 |
| Metoprolol Succinate | 701 | $7,155 |
| Propafenone Hcl ErPropafenone Hcl | 24 | $6,740 |
| EdarbiAzilsartan Medoxomil | 16 | $5,468 |
| Nitroglycerin PatchNitroglycerin | 148 | $4,636 |
| Amiodarone Hcl | 342 | $4,552 |
| ClopidogrelClopidogrel Bisulfate | 400 | $3,960 |
| Nebivolol Hcl | 90 | $3,478 |
| Ranolazine ErRanolazine | 60 | $3,304 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $180 | $611,866832 claims |
| NovartisEntresto | $1,583 | $233,871293 claims |
| Johnson & JohnsonXarelto | $164 | $165,815199 claims |
| Boehringer IngelheimJardiance | $113 | $130,672192 claims |
| AstraZenecaFarxiga, Brilinta | $255 | $114,984180 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 144 cardiovascular disease providers in Mississippi.
Other cardiovascular disease in Jackson
- Donny StokesJackson$207K
- James BenslerJackson$64K
- Michael HallJackson$54K
- Tahsin QarqishJackson$39K
- Christopher LatourJackson$33K
- Varun SardarJackson$31K
- Olurotimi BaderoJackson$20K
- Michael PaymentJackson$16K
- Douglas HarkinsJackson$14K
- Aditya SabharwalJackson$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.